Little is known about the impact of appropriate dosing on the effectiveness and safety of two new agents used in patients with non-valvular atrial fibrillation. Paul Burton, MD, PhD, Vice President of Medical Affairs at Janssen, discusses data presented at ACC.16 in Chicago.